Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma
| Autor: | Masami Takeuchi, Hiroyuki Takamatsu, Yasuhito Suehara, Yoshiaki Usui, Kelly Endean, Kosei Matsue, Manabu Fujisawa, Kota Fukumoto, Kentaro Narita |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Multivariate analysis Carcinogenesis IgA myeloma Immunoglobulin light chain IgG myeloma survival Gastroenterology Best response 03 medical and health sciences 0302 clinical medicine Internal medicine Confidence Intervals Humans Medicine heavy/light chain assay Risk factor Multiple myeloma Aged Retrospective Studies Aged 80 and over Analysis of Variance biology business.industry Hazard ratio Original Articles General Medicine Middle Aged medicine.disease Confidence interval Immunoglobulin A Oncology Immunoglobulin G 030220 oncology & carcinogenesis biology.protein Original Article Female Immunoglobulin Light Chains Antibody Immunoglobulin Heavy Chains Multiple Myeloma business 030215 immunology |
| Zdroj: | Cancer Science |
| ISSN: | 1347-9032 |
| DOI: | 10.1111/cas.13125 |
| Popis: | Immunoglobulin (Ig) heavy/light chain (HLC) assays enable the separate quantification of the different light chain types of each Ig class. We retrospectively analyzed the correlation of heavy/light chain ratio (HLCR) with clinical status and its impact on outcome in 120 patients with multiple myeloma (MM). Abnormal HLCR was seen more frequently in patients with poorer myeloma response, and it appeared to be more sensitive for detecting clonality in IgA myeloma compared to IgG myeloma after treatment. Among the 85 patients who achieved ≥VGPR, the patients remained HLCR abnormal were showed significantly shorter overall survival (OS) compared to those achieving a normal HLCR (not reached vs 55.5 months, P = 0.032). This correlation was seen in IgA myeloma patients (not reached vs 30.1 months, P = 0.014), but not in IgG myeloma patients when patients were analyzed separately. Univariate and multivariate analysis of factors that may affect survival identified abnormal HLCR at the best response as the only independent risk factor (hazard ratio, 4.7; 95% confidence interval, 1.4 - 15.26; P = 0.012) for shorter OS in this subset of patients. This study highlighted the HLC assay as a prognostic predictor in patients with IgA myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text